You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

extranodal

Showing 1 - 25 of 792
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Ascertaining Radiologic Prognostic Importance of Extranodal

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Extranodal extension
  • Omaha, Nebraska
  • +11 more
Jul 11, 2023

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Tumor Deposits in Colorectal Cancers

Completed
  • Extranodal Extension
  • Colorectal Resection
  • (no location specified)
Jun 27, 2023

Radiological Extranodal Extension in Oropharyngeal Carcinoma

Active, not recruiting
  • Head and Neck Carcinoma
    • Boston, Massachusetts
    • +2 more
    Sep 29, 2022

    Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

    Active, not recruiting
    • Extranodal NK/T-cell Lymphoma
    • B-MAD chemotherapy
    • Bangkok, Thailand
      King Chulalongkorn Memorial Hospital
    May 7, 2022

    Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

    Not yet recruiting
    • Primary Extranodal Lymphoma
    • DLBCL
    • (no location specified)
    Apr 6, 2022

    Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

    Not yet recruiting
    • Extranodal NK/T Cell Lymphoma
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jun 16, 2022

    Lymphoma Trial in Milan (clarithromycin, oral, high dose)

    Completed
    • Lymphoma
    • clarithromycin, oral, high dose
    • Milan, Italy
      Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
    Aug 10, 2022

    Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of

    Recruiting
    • Extranodal Natural Killer T Cell Lymphoma
    • Tislelizumab combined with Liposomal mitoxantrone hydrochloride
    • Maintenance of tislelizumab
    • Beijing, China
    • +5 more
    Jul 15, 2022

    Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

    Available
    • Extranodal NK/T-cell Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Mar 18, 2022

    Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

    Not yet recruiting
    • Extranodal Natural Killer/T-cell Lymphoma
    • circulate free methylated EBV DNA
    • Nanjing, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 19, 2022

    Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

    Recruiting
    • Extranodal NK T Cell Lymphoma
    • NK-Cell Leukemia
    • Anti-CD56 CAR T
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Jul 10, 2023

    Tumor Deposits for Patients With Papillary Thyroid Carcinoma

    Completed
    • Exploring the Prognostic Value of Tumor Deposits PTC Patients
    • surgery
    • Guangzhou, Guangdong, China
      Nanfang Hospital, Southern Medical University
    Sep 18, 2023

    Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

    Recruiting
    • Extranodal NK/T-cell Lymphoma
    • VT-EBV-N
    • Placebo
    • Busan, Korea, Republic of
    • +7 more
    Apr 28, 2022

    Extranodal Lymphoma or Lymphoma of Rare Pathological Types

    Not yet recruiting
    • Lymphoma
    • +8 more
    • No interventions need to be specified for this study
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 15, 2023

    Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

    Recruiting
    • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
    • +2 more
    • Anti-PD-1 monoclonal antibody
    • +4 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Feb 23, 2022

    Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

    Active, not recruiting
    • Lymphoma, Extranodal NK-T-Cell
    • Seoul, Korea, Republic of
      81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
    Sep 22, 2021

    T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

    Recruiting
    • T-cell Non-Hodgkin Lymphoma
    • Lymphoma, Extranodal NK-T-Cell
    • Busan, Korea, Republic of
    • +1 more
    Aug 17, 2022

    Lymphoma, Extranodal NK-T-Cell Trial in Shanghai (Pembrolizumab, Involved Field Radiation Therapy)

    Recruiting
    • Lymphoma, Extranodal NK-T-Cell
    • Shanghai, China
      Shanghai Rui-Jin Hospital
    Mar 29, 2022